---
schema_version: "secwatch.filing_event.v1"
accession: "0001411690-25-000045"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:15:46.887270+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bionano Q1 revenue $6.5M, down 26% YoY; FY2025 guidance $26-30M

## Summary
- Q1 revenue $6.5M vs $8.8M YoY, down 26%; GAAP gross margin improved to 46% from 32%.
- Flowcell sales 6,994 units (-15% YoY); to routine customers up 1% after adjusting for new adds.
- GAAP operating expense $11.4M, down 66% YoY from cost cuts and restructuring.
- Cash, equivalents and investments $29.2M; cash runway extended into Q1 2026.
- FY2025 revenue guidance updated to $26-30M; Q2 revenue expected $6.3-6.8M.

## SEC filing metadata
- accession: 0001411690-25-000045
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000141169025000045/0001411690-25-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000141169025000045/bngo-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411690-25-000045
- JSON: https://secwatch.observer/filing/0001411690-25-000045.json
- Plain text: https://secwatch.observer/filing/0001411690-25-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.